Accretion Dilution Analysis: How to Model M&A EPS Impact
The Core Concept
When a company acquires another, two things happen to the numerator and denominator of EPS. The numerator (net income) changes because you’re adding the target’s earnings, but also adjusting for new interest expense, lost interest income on cash used, incremental D&A from purchase accounting, and synergies. The denominator (shares) changes if you issue stock as part of the deal consideration.
If the combined effect increases EPS → accretive. If it decreases EPS → dilutive.
The Formula
Key Adjustments to Net Income
| Adjustment | Direction | Explanation |
|---|---|---|
| Target’s Net Income | Add | Earnings from the acquired company |
| Interest on New Debt | Subtract | After-tax cost of debt used to fund the deal |
| Lost Interest on Cash Used | Subtract | After-tax opportunity cost of deploying cash |
| Incremental D&A (write-ups) | Subtract | After-tax impact of asset write-ups from purchase accounting |
| Cost Synergies | Add | After-tax cost savings from the combination |
| Revenue Synergies | Add | After-tax incremental earnings from revenue enhancement |
| Financing Fee Amortization | Subtract | After-tax amortization of debt issuance costs |
Step-by-Step Process
Step 1 — Establish Standalone EPS
Start with the acquirer’s projected standalone EPS for the year the deal closes. This is your benchmark. Use consensus estimates or your own financial model.
Step 2 — Calculate the Purchase Price
Offer price per share × target’s diluted shares = equity purchase price. Add transaction fees and any debt refinancing for total uses. Determine the funding mix: how much cash, debt, and stock. This drives the adjustments in the next step.
Step 3 — Model the Income Statement Adjustments
For a cash deal: subtract after-tax interest on new debt and after-tax lost interest income on cash spent. For a stock deal: no interest adjustments, but shares outstanding increase. For both: subtract after-tax incremental D&A from write-ups and add after-tax synergies.
Step 4 — Calculate Pro Forma Shares
Acquirer’s existing diluted shares + new shares issued to target shareholders (if stock deal). For a mixed deal, calculate shares issued based on the stock portion of the consideration and the exchange ratio.
Step 5 — Compute Pro Forma EPS and Compare
Divide adjusted pro forma net income by pro forma shares. Compare to standalone EPS. Report the dollar and percentage accretion or dilution. Run sensitivities on synergies and the consideration mix.
The P/E Shortcut
For an all-stock deal, there’s an intuitive shortcut: if the acquirer’s P/E is higher than the target’s P/E (on the deal price), the deal is accretive. If lower, it’s dilutive. This is called P/E arbitrage — the acquirer is buying earnings at a lower multiple than its own stock trades at.
| Scenario | All-Cash Deal | All-Stock Deal |
|---|---|---|
| EPS Impact | More accretive (no share dilution) | More dilutive (share count increases) |
| Balance Sheet Impact | Higher leverage | No new debt |
| Key Cost | After-tax interest expense | Dilution to existing shareholders |
| Accretive When… | Target’s earnings yield > after-tax cost of debt | Acquirer’s P/E > target’s P/E at deal price |
Impact of Synergies on Accretion/Dilution
Many deals that appear dilutive on a standalone basis become accretive once synergies are factored in. This is often the primary justification boards use to approve premium-priced acquisitions. However, synergies take time to realize — model them with a phase-in schedule (e.g., 25% in Year 1, 75% in Year 2, 100% in Year 3).
Key Takeaways
- Accretion = pro forma EPS > standalone EPS. Dilution = pro forma EPS < standalone EPS.
- Cash deals are more accretive but increase leverage. Stock deals dilute shares but avoid new debt.
- For all-stock deals: acquirer P/E > target P/E at deal price → accretive.
- Always model accretion/dilution both with and without synergies.
- Accretion/dilution alone shouldn’t drive deal decisions — strategic fit and long-term value creation matter more.
Frequently Asked Questions
Is an accretive deal always a good deal?
No. A deal can be accretive to EPS but still destroy shareholder value if the acquirer overpays relative to the target’s intrinsic value. EPS accretion can be manufactured through P/E arbitrage (buying low-P/E companies) without creating any real economic value. Always evaluate the deal on a DCF basis alongside accretion/dilution.
How do I model a deal that’s half cash and half stock?
Split the purchase price 50/50. For the cash portion: model new debt and lost interest income. For the stock portion: calculate new shares issued at the exchange ratio. Then combine all adjustments into one pro forma EPS calculation. Run sensitivities on the mix (e.g., 60/40, 70/30) to show the board the tradeoffs.
What’s a typical accretion/dilution threshold for a deal to proceed?
Most boards expect a deal to be accretive within 1–2 years, with synergies. Immediate dilution of 3–5% is often tolerable if the strategic rationale is strong and the path to accretion is clear. Dilution beyond 5–10% in the first year raises red flags and may face shareholder pushback.
How do purchase accounting adjustments affect accretion/dilution?
Asset write-ups create incremental depreciation and amortization charges that reduce pro forma net income and push the deal toward dilution. A $500M intangible write-up amortized over 10 years creates $50M of annual pre-tax D&A — at a 25% tax rate, that’s $37.5M less net income per year.
Why do analysts show accretion/dilution at different synergy levels?
Because synergy realization is uncertain. Showing the deal at 0%, 50%, and 100% of expected synergies lets the board see the full range of outcomes. If the deal is only accretive at 100% synergies, it depends entirely on perfect execution — a risky proposition that the board should understand before approving.